Bedel Financial Consulting, Inc. Gilead Sciences, Inc. Transaction History

Bedel Financial Consulting, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$57.72 - $65.01 $103,261 - $116,302	-1,789 Closed	0 $0
Q1 2022 Apr 19, 2022	BUY	$57.92 - $72.58 $8,166 - $10,233	141 Added 8.56%	1,789 $106,000
Q4 2021 Jan 11, 2022	BUY	$64.88 - $73.64 $64 - $73	1 Added 0.06%	1,648 $120,000
Q2 2021 Aug 03, 2021	SELL	$63.47 - $69.35 $36,368 - $39,737	-573 Reduced 25.81%	1,647 $113,000
Q1 2021 Apr 26, 2021	BUY	$60.0 - $68.46 $113,820 - $129,868	1,897 Added 587.31%	2,220 $143,000
Q4 2020 Feb 02, 2021	SELL	$56.65 - $64.55 $5,665 - $6,455	-100 Reduced 23.64%	323 $19,000
Q3 2020 Oct 20, 2020	BUY	$62.1 - $78.08 $6,210 - $7,808	100 Added 30.96%	423 $27,000
Q2 2020 Jul 14, 2020	SELL	$72.34 - $84.0 $434 - $504	-6 Reduced 1.82%	323 $25,000
Q1 2020 May 06, 2020	BUY	$62.63 - $80.22 $563 - $721	9 Added 2.81%	329 $25,000
Q4 2018 Jan 28, 2019	SELL	$60.54 - $79.0 $9,081 - $11,850	-150 Reduced 31.91%	320 $20,000
Q3 2018 Nov 01, 2018	BUY	$71.28 - $78.92 $17,820 - $19,730	250 Added 113.64%	470 $35,000
Q2 2018 Jul 18, 2018	BUY	$64.88 - $75.68 $64 - $75	1 Added 0.46%	220 $16,000
Q1 2018 May 03, 2018	BUY	$72.84 - $88.8 $15,951 - $19,447	219 New	219 $17,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Bedel Financial Consulting, Inc., based on Form 13F filings with the SEC.

Stay updated on Bedel Financial Consulting, Inc. with notifications on news.